Oncology Pharma Inc. (ONPH)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: May 13, 2025
Oncology Pharma Revenue
In the fiscal year ending March 31, 2013, Oncology Pharma had annual revenue of $10.21K, down -92.42%. Oncology Pharma had revenue of $472.31K in the quarter ending December 31, 2011.
Revenue
10.21K
Revenue Growth
-98.44%
P/S Ratio
0.38
Revenue / Employee
10.21K
Employees
1
Market Cap
3.87K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2013 | 10.21K | -124.49K | -92.42% |
| Jun 30, 2011 | 134.70K | -1.05M | -88.59% |
| Mar 31, 2004 | 1.18M | -2.10M | -63.99% |
| Mar 31, 2003 | 3.28M | -392.00K | -10.68% |
| Mar 31, 2002 | 3.67M | -340.00K | -8.47% |
| Mar 31, 2001 | Pro | Pro | Pro |
| Mar 31, 2000 | Pro | Pro | Pro |
| Mar 31, 1999 | Pro | Pro | Pro |
| Jun 30, 1998 | Pro | Pro | Pro |
| Jun 30, 1997 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 215.62M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| American Oncology Network | 1.76B |
| BioStem Technologies | 301.83M |
Oncology Pharma News
- 10 months ago - Median Technologies Partners with a Top 10 Oncology Pharma Company to Apply AI for Imaging Biomarker Discovery - Business Wire
- 3 years ago - Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System - Accesswire
- 3 years ago - Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System - Accesswire
- 3 years ago - Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development - Accesswire
- 3 years ago - Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development - Accesswire
- 3 years ago - Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer - Accesswire
- 3 years ago - Oncology Pharma Reports on Progress with Ribera Solutions - Accesswire
- 3 years ago - Oncology Pharma Releases Further Feasibility Studies, Data and Capacities - Accesswire